IMVT$23.98
$23.845
Chart
Performance
Key Stats
AI IMVT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldImmunovant shows promise in the biotech sector with strong fundamental backing but faces mixed technical signals and the inherent risks of clinical-stage development. Investors should monitor clinical trial progress and market sentiment.
Thematic
Immunovant operates in the growing autoimmune disease treatment market, with its FcRn inhibitor technology targeting significant unmet needs. The thematic potential is linked to successful clinical trial outcomes and market adoption.
Fundamental
Immunovant demonstrates a strong balance sheet with substantial cash reserves and minimal debt, providing a solid foundation for its clinical development programs. However, profitability metrics are negative due to its stage of development.
Technical
Immunovant's stock shows a mixed technical picture. While it trades above its short-term moving averages, longer-term indicators and some oscillators suggest potential headwinds or consolidation. The overall trend leans cautiously optimistic.
| Factor | Score |
|---|---|
| Autoimmune Disease Treatment Market | 75 |
| FcRn Inhibitor Technology | 70 |
| Biotechnology Innovation | 70 |
| Competitive Landscape | 60 |
| Regulatory Environment | 65 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 10 |
| Balance Sheet Health | 100 |
| Cash Flow | 35 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (4)
Positive EPS Surprises
The company has shown a trend of positive EPS surprises, with the most recent quarter (2025 Q2) beating estimates by 10.69%.
Strong Cash Position
As of Q1 2025, the company holds $713.97 million in cash and cash equivalents, providing significant liquidity and financial flexibility.
Bearish Points (7)
Consistent EPS Misses
Despite some positive surprises, the company has a history of missing EPS estimates, with significant misses in Q4 2024 (-23.94%) and Q1 2024 (-21.88%).
Negative Net Income
The company has consistently reported negative net income for the periods available (e.g., -413.84 million in Q1 2025), indicating ongoing unprofitability.
Calendar
August 2025
4
Next Earnings Date
H: $-0.62
A: $-0.69
L: $-0.77
Profile
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Seasonals
Price Target
41.57 USD
The 39 analysts offering 1 year price forecasts for IMVT have a max estimate of 61.00 and a min estimate of 17.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major pharmaceutical company with a significant presence in oncology and immunology, including the development of antibody-drug conjugates (ADCs), which are a class of biologics related to IMVT's antibody-focused approach. Also involved in a global development and commercialization agreement for ADC candidates. [1, 7, 8, 9, 12, 14, 36, 39, 43, 47]
Weight: 90
A leading biopharmaceutical company with a strong focus on oncology and immunology, including checkpoint inhibitors and CAR-T treatments, which are advanced antibody-based therapies. [1, 4, 12, 21, 27, 29, 32, 40]
Weight: 90
A major multinational pharmaceutical company with a substantial oncology division and significant investment in antibody-drug conjugates (ADCs), demonstrated by its acquisition of Seagen. [1, 4, 7, 8, 40]
Weight: 88
A global leader in monoclonal antibodies and targeted therapies, with a dominant position in the oncology market, actively developing and commercializing a wide range of biologic therapeutics. [1, 3, 4, 12]